TY - JOUR
T1 - Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer
AU - Chadha, Awalpreet S.
AU - Khoo, Allison
AU - Aliru, Maureen L.
AU - Arora, Harpreet K.
AU - Gunther, Jillian R.
AU - Krishnan, Sunil
N1 - Funding Information:
Dr. Krishnan reports research support from Merck, Genentech, and Celgene for pancreatic cancer clinical trials and from Polaris Pharma for preclinical studies in pancreatic cancer. He also reports research grant support from the NIH for pancreatic cancer preclinical studies.
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - The outcomes for treatment of pancreatic cancer have not improved dramatically in many decades. However, the recent promising results with combination chemotherapy regimens for metastatic disease increase optimism for future treatments. With greater control of overt or occult metastatic disease, there will likely be an expanding role for local treatment modalities, especially given that nearly a third of pancreatic cancer patients have locally destructive disease without distant metastatic disease at the time of death. Technical advances have allowed for the safe delivery of dose-escalated radiation therapy, which can then be combined with chemotherapy, targeted agents, immunotherapy, and nanoparticulate drug delivery techniques to produce novel and improved synergistic effects. Here we discuss recent advances and future directions for multimodality therapy in pancreatic cancer.
AB - The outcomes for treatment of pancreatic cancer have not improved dramatically in many decades. However, the recent promising results with combination chemotherapy regimens for metastatic disease increase optimism for future treatments. With greater control of overt or occult metastatic disease, there will likely be an expanding role for local treatment modalities, especially given that nearly a third of pancreatic cancer patients have locally destructive disease without distant metastatic disease at the time of death. Technical advances have allowed for the safe delivery of dose-escalated radiation therapy, which can then be combined with chemotherapy, targeted agents, immunotherapy, and nanoparticulate drug delivery techniques to produce novel and improved synergistic effects. Here we discuss recent advances and future directions for multimodality therapy in pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=84995390476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995390476&partnerID=8YFLogxK
U2 - 10.1016/j.semradonc.2016.05.002
DO - 10.1016/j.semradonc.2016.05.002
M3 - Review article
C2 - 27619253
AN - SCOPUS:84995390476
SN - 1053-4296
VL - 26
SP - 320
EP - 337
JO - Seminars in radiation oncology
JF - Seminars in radiation oncology
IS - 4
ER -